Showing results (1-10 of 26) with videos related to
Sort By:
Pageof 3
Methods in Molecular Biology (Clifton, N.J.)|August 6, 2013
Immunocompetent mouse model of ovarian cancer for in vivo imagingSelene Nunez-Cruz, Nathalie SchollerJournal of Visualized Experiments : Jove|December 24, 2010
An orthotopic model of serous ovarian cancer in immunocompetent mice for in vivo tumor imaging and monitoring of tumor immune responsesSelene Nunez-Cruz, Denise C Connolly, Nathalie SchollerJournal of Immunological Methods|September 15, 2010
Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platformAizhi Zhao, Selene Nunez-Cruz, Chunsheng Li, et al.Biochemical and Biophysical Research Communications|September 17, 2023
F77 antigen is a promising target for adoptive T cell therapy of prostate cancerPayal Grover, Selene Nunez-Cruz, John Leferovich, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 20, 2019
Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling PathwayQian Zhang, Hong Y Wang, Xiaobin Liu, et al.Neoplasia (New York, N.Y.)|December 11, 2012
Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularizationSelene Nunez-Cruz, Phyllis A Gimotty, Matthew W Guerra, et al.Cancer Immunology Research|November 29, 2017
High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma ModelSarah A Richman, Selene Nunez-Cruz, Babak Moghimi, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 8, 2008
Differential requirement for the SAP-Fyn interaction during NK T cell development and functionSelene Nunez-Cruz, W C Janice Yeo, Jennifer Rothman, et al.Nano Letters|January 27, 2017
Improving T Cell Expansion with a Soft TouchLester H Lambert, Geraldine K E Goebrecht, Sarah E De Leo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2020
Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell TherapyEduardo Huarte, Roddy S O'Connor, Michael T Peel, et al.Pageof 3